Acadian Asset Management’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Acadian Asset Management’s Portfolio OMED Stock Details OMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-241,507	Closed	-$252K	–	2209
2019 Q1	$252K	Buy	241,507 +46,400	+24%	+$37.8K	﹤0.01%	1298
2018 Q4	$146K	Buy	195,107 +40,353	+26%	+$60.7K	﹤0.01%	1186
2018 Q3	$329K	Buy	154,754 +16,263	+12%	+$39K	﹤0.01%	973
2018 Q2	$320K	Buy	138,491 +81,698	+144%	+$238K	﹤0.01%	969
2018 Q1	$181K	Buy	+56,793	New	+$156K	﹤0.01%	1083
2017 Q2	–	Sell	-31,353	Closed	-$289K	–	1767
2017 Q1	$289K	Buy	+31,353	New	+$275K	﹤0.01%	983

Acadian Asset Management's OMED Position: Q2 2019 in Review

Acadian Asset Management sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q2 2019, closing a stake of 241,507 shares — an estimated $252K sold.

Acadian Asset Management first reported a position in OMED in Q1 2017 and held it in 6 quarters. The position peaked at $329K in Q3 2018. 0 funds tracked by Wall St. Rank hold OMED as of Q2 2019.

Acadian Asset Management reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
Acadian Asset Management sold 241,507 OncoMed Pharmaceuticals, Inc. shares in Q2 2019, an estimated $252K.
Acadian Asset Management first reported a position in OncoMed Pharmaceuticals, Inc. in Q1 2017 and held it in 6 quarters.
Acadian Asset Management's OncoMed Pharmaceuticals, Inc. position peaked at $329K in Q3 2018.
0 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q2 2019.

Based on Acadian Asset Management's 13F filing for Q2 2019, filed 8 Aug 2019.